Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings is well positioned to capture a large portion of the market for metastatic uveal melanoma, as KIMMTRAK has been shown to significantly improve overall survival compared to other treatments. Additionally, the company's deep pipeline of drug candidates in various therapeutic areas provide potential for further revenue growth in the future. With a strong commercial base and potential expansions into new markets and indications, Immunocore has a positive outlook for its stock performance.

Bears say

Immunocore Holdings is a commercial-stage biotechnology company with a deep pipeline in multiple therapeutic areas. However, due to unproven clinical benefit and the need for additional funding, there is a potential downside of 5% to the company's base case. In addition, there is strong competition in solid tumor indications and no guarantee of success for the company's early stage programs. Thus, a negative outlook is justified given the uncertainty surrounding Immunocore's future prospects.

Immunocore Holdings (IMCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 6 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.